Clinical trials: Type 2 Diabetes (T2D)
Type 2 Diabetes
Specific Clinical Experience Investigation for Long-term Use of Bydureon.
To confirm the safety and efficacy of Bydureon in long-term use in Japanese patients with type 2 diabetes mellitus under actual drug use.
- Trial name
- NCT01940770
- Where
- 47 sites in Japan
- Volunteers
- 1,137 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec…
- Trial name
- NCT07112339
- Testing
- Insulin icodec, Basal insulin analogues
- Where
- 75 sites in Canada, Germany and 1 more
- Volunteers
- 586 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
This trial is globally conducted. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus Sitagliptin in Subjects with Type 2 Diabetes…
- Trial name
- PIONEER 7 (NCT02849080)
- Testing
- semaglutide, sitagliptin
- Where
- 83 sites in United States, Argentina and 8 more
- Volunteers
- 504 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
Primary Objective: To identify a best fasting plasma glucose (FPG) target for Chinese type 2 diabetes patients using insulin glargine which can provide the highest control rate of glycated hemoglobin (HbA1c) < 7%.
- Trial name
- NCT02545842
- Testing
- INSULIN GLARGINE
- Where
- 44 sites in China
- Volunteers
- 947 people
- Sponsor
- Sanofi
Prediabetic State, Diabetes Mellitus, Type 2
Noninvasive Skin Spectroscopy for Diabetes Screening
The objective of this study is to assess the performance of a noninvasive device for the early screening of Diabetes Mellitus.
- Trial name
- NCT00358254
- Where
- 2 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- InLight Solutions
Diabetes Mellitus Type 2
A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.
- Trial name
- NCT02097277
- Testing
- BMS-986036
- Where
- 16 sites in United States, Canada
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb
Diabetes Mellitus Type 2
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor compared to placebo in patients with type 2 diabetes.
- Trial name
- NCT00111670
- Testing
- DPP-IV Inhibitor
- Where
- 40 sites in United States, Bulgaria and 7 more
- Volunteers
- 291 people
- Sponsor
- Hoffmann-La Roche
Obesity, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes
This is a multiple dose study to evaluate the safety, tolerability, PK, and PD of K-757 and K-833 when co-administered in overweight/obese patients with Type 2 diabetes mellitus (T2DM)
- Trial name
- NCT06305351
- Testing
- K-757 and K-833 QD, K-757 and K-833 BID
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- TriGemX Bio, Inc.
Type 2 Diabetes Mellitus
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
This study will evaluate the efficacy and safety of vildagliptin 50 mg bid in elderly patients with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT01257451
- Testing
- Vildagliptin
- Where
- 46 sites in Belgium, Bulgaria and 5 more
- Volunteers
- 431 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy
Primary Objective: To investigate the efficacy(HbA1c) at 6 months after adding basal insulin therapy (insulin glargine) to dipeptidyl peptidase-IV (DPP-IV) and metformin plus or minus sulphonylurea Secondary Objectives: 1.
- Trial name
- TED (NCT02027753)
- Testing
- INSULIN GLARGINE, Metformin, DPP-4 inhibitor
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients
The purpose of this study is to investigate safety and tolerability after high Single Ascending Oral Doses of AZD1656.
- Trial name
- NCT01221545
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Type II Diabetes
A Study to Assess the Effect of Food on HR20033 and Pharmacokinetic After Multiple Dose in Healthy Volunteers
According to the objective, the trial is constituted by two study groups: one is food effect assessment group, and another is multiple dose pharmacokinetic assessment group.
- Trial name
- NCT05120219
- Testing
- FDC tablet
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Type 2 Diabetes
The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes
The purpose of this study is to prove that the group treated with D745 in combination added that the reduction of HbA1c superior to placebo treated group added in combination.
- Trial name
- NCT05566028
- Testing
- D745 formulation I, D745 formulation II
- Where
- South Korea
- Volunteers
- 172 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Type2 Diabetes Mellitus
The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
This research is a randomized, double-blind,controlled trial. 456 Chinese subjects with Type 2 Diabetes Mellitus will be enrolled in the trial.
- Trial name
- NCT03239119
- Testing
- rE-4 5 mcg, rE-4 10 mcg
- Volunteers
- 456 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Diabetes Mellitus, Type 2, Chronic Renal Insufficiency
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
The purpose of this study is to determine the safety and tolerability of an investigational drug in patients with Type 2 Diabetes Mellitus (a specific type of diabetes) and Chronic Renal Insufficiency (inadequate kidney function).
- Trial name
- NCT00095056
- Testing
- sitagliptin, glipizide
- Volunteers
- 91 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus
To demonstrate that the fixed dose combination of telmisartan and amlodipine is more effective in lowering blood pressure.
- Trial name
- NCT00877929
- Testing
- Telmisartan 80, Amlodipine 10
- Where
- 65 sites in United States, Argentina and 7 more
- Volunteers
- 706 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type II
GOLO Open-Label Pilot 1
The objective of this open-label pilot study is to evaluate the effect of the commercially available GOLO for Life (GFL) weight management program on body weight in a type 2 diabetic patient population after approximately 3…
- Trial name
- NCT03478202
- Testing
- GOLO RELEASE
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Golo
Diabetes Mellitus, Non-Insulin-Dependent
An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes
The purpose of this study is to determine if an investigational drug is safe and efficacious for poorly controlled type 2 diabetes mellitus.
- Trial name
- NCT00065312
- Testing
- naveglitazar
- Where
- 42 sites in United States
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects
The principal objective of this study is to evaluate the safety and tolerability of repeated doses of EV-077-3201-2TBS given to diabetic subjects over a 4 week treatment period.
- Trial name
- NCT01551381
- Testing
- EV-077
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Evolva SA
Hypertension, Diabetes
Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
The purpose of this study was to evaluate the antihypertensive and antiglycemic effects, as well as the safety and tolerability of TAK-491 (azilsartan medoxomil), once daily (QD), in stage 1 hypertensive, type 2 diabetes mellitus…
- Trial name
- NCT01496430
- Testing
- Azilsartan medoxomil
- Where
- 68 sites in United States
- Volunteers
- 105 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.